Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.
MGD009 (MGD009) binds human and cynomolgus monkey CD3 and B7-H3 with KD values of 13.9, 14.7, 24.6, and 30.2 nM for human CD3ε/δ, cynomolgus CD3ε/δ, human B7-H3-His, and cynomolgus B7-H3-His, respectively[1].Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, and Detroit562 cells) mediates redirected killing of multiple B7-H3-expressing tumor lines[1].Obrindatamab (0.01-1000 ng/mL; PBMCs and A498 cells) mediated T-cell activation and proliferation is target antigen dependent[1].
Obrindatamab (MGD009; 0.004-1 mg/kg; i.v.) inhibits growth and tumor regression of B7-H3-expressing tumor xenografts in human T cell or PBMC-reconstituted mice[1].
References:
[1]. Paul M, et, al. MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors.